Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Eckhardt

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Oncology|November 13, 2004
A phase I and pharmacokinetic study of BAY59: a novel taxaneN Ramnath, J Hamm, G Schwartz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft modelL A Hammond, S G Hilsenbeck, S G Eckhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2005
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsS N Holden, S G Eckhardt, R Basser, et al.
Cancer Research|March 10, 1999
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft modelC D Britten, S G Hilsenbeck, S G Eckhardt, et al.
Journal of Clinical Pharmacology|March 10, 2000
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancersH Zhou, L Choi, H Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancerJ Nemunaitis, J T Holmlund, M Kraynak, et al.
Investigational New Drugs|September 21, 2011
Phase I combination study of trabectedin and capecitabine in patients with advanced malignanciesLia Gore, E Rivera, M Basche, et al.
The British Journal of Surgery|March 19, 2019
Changes in gut hormones, glycaemic response and symptoms after oesophagectomyJ A Elliott, N G Docherty, C F Murphy, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2012
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumorsS Leong, S G Eckhardt, E Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignanciesM A Villalona-Calero, T Petit, J Kuhn, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Oncology|November 13, 2004
A phase I and pharmacokinetic study of BAY59: a novel taxaneN Ramnath, J Hamm, G Schwartz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft modelL A Hammond, S G Hilsenbeck, S G Eckhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2005
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumorsS N Holden, S G Eckhardt, R Basser, et al.
Cancer Research|March 10, 1999
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft modelC D Britten, S G Hilsenbeck, S G Eckhardt, et al.
Journal of Clinical Pharmacology|March 10, 2000
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancersH Zhou, L Choi, H Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancerJ Nemunaitis, J T Holmlund, M Kraynak, et al.
Investigational New Drugs|September 21, 2011
Phase I combination study of trabectedin and capecitabine in patients with advanced malignanciesLia Gore, E Rivera, M Basche, et al.
The British Journal of Surgery|March 19, 2019
Changes in gut hormones, glycaemic response and symptoms after oesophagectomyJ A Elliott, N G Docherty, C F Murphy, et al.
Cancer Chemotherapy and Pharmacology|May 25, 2012
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumorsS Leong, S G Eckhardt, E Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignanciesM A Villalona-Calero, T Petit, J Kuhn, et al.
Pageof 10